Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 140 for “"pdac"”.
-
Heparan Sulfate Proteoglycans in Pancreatic Ductal Adenocarcinoma (PDAC)
… effector for pancreatic ductal adenocarcinoma (PDAC) progression whose surface expression is driven by KRAS*. By leveraging various PDAC models, we found that surface SDC1 expression was initially diminished upon mutant KRAS (KRAS*) signaling blockade but recovered in tumor cells that bypass …
-
Single cell and spatial analysis characterize metabolic DPEP1+ fibroblasts in PDAC
<p>Pancreatic ductal adenocarcinoma (PDAC) is highly malignant and exhibits aggressive progression patterns, resists conventional treatments, and poses significant challenges to patient survival, necessitating urgent research and development of novel therapeutic approaches. Understanding …
-
Role of Methyltransferase Like-3 (Mettl3) In Pancreatic Ductal Adenocarcinoma (Pdac) Progression
<p>Pancreatic Ductal Adenocarcinoma (PDAC) is an aggressive cancer with about a 10% five-year survival rate. The grim prognostic situation of pancreatic cancer patients underlines the need to identify novel molecular targets. Recent studies have brought to attention, the need to therapeutically …
-
The role of tissue-resident immune cells in PanIN to PDAC progression
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer deaths worldwide. PDAC is recalcitrant to current immunotherapies, largely due to local suppression of anti-tumour immunity. Tissue-resident group 2 innate lymphoid cells (ILC2) are emerging as important immune …
-
Micro- and nano-scale polymer-on-polymer stamping of the polyelectrolytes SPS and PDAC
… solution including a large amount of salt. PDAC can be stamped from either concentrated ethanol based inks or from a dilute aqueous one. The more concentrated ink produces prints faster and more reliably, but causes more damage to the stamps used. PDAC can also be used to print nano-scale …
-
Decoding The Tumor and Immune Microenvironment In Pdac and Breast Cancer By Single Cell Sequencing.
… states of T cell clones from human PDACs into a T cell culture product for adoptive cell therapy. Second, we examined the potential role of radiotherapy in inducing an immune response in hormone receptor positive breast tumors.</p>
-
Molecular dissection of macrophage-tumour cell interactions to identify novel treatment strategies for pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive forms of adult tumours with a median survival time of twelve months. PDAC is highly resistant to conventional therapy which includes surgical resection of the tumour, radiation treatment and chemotherapy. PDAC cells are highly …
-
Investigating the impact of ageing on the tumour microenvironment and its crosstalk with malignant cells in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is characterised by an extensive tumour microenvironment (TME), which contributes to disease progression and therapy response. PDAC primarily affects elderly individuals as patients are typically diagnosed when 70 years old or older. While ageing has been …
-
Investigation of the effect of disulfiram on the chemoresistance and invasiveness in pancreatic cancer cells
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide with a mortality to incidence ratio of 94%. It is the 10th most common cancer in the UK with a 5-year survival less than 7%. In contrast to the improved therapeutic outcomes in many other cancers, the prognosis of …
-
PROGRAMMED ADDICTION OF PANCREATIC CANCER TO NUCLEOTIDE METABOLISM BY THE TUMOR MICROENVIRONMENT
Pancreatic ductal adenocarcinoma (PDAC) is one of the fastest growing malignancy, yet PDAC cells face a harsh tumor microenvironment (TME) of poor nutrient availability. To adapt, they were shown to exploit stellate cells, the predominant stromal cells, for growth-promoting nutrients. However, …
-
The Functional Contribution of Adaptive Immunity In The Biology of Pancreatic Cancer and Therapeutic Targeting of Oncogenic Kras
… Kalluri</p> <p>Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer related deaths in the USA(https://seer.cancer.gov/statfacts/html/pancreas.html), whereby survival remains poor despite advances in surgical technique and new combination chemotherapies. Immune checkpoint …
-
Investigating The Role of Cd109 In Pancreatic Ductal Adenocarcinoma
<p>Pancreatic Ductal Adenocarcinoma (PDAC) is the 3rd leading cause of cancer death in the US. We performed loss of function genomic screening on a cohort of four patient derived PDAC cell populations and our data shows a cell surface receptor CD109 to be a common vulnerability, the biologic role …
-
Investigating the Role of the Lysine-Specific Demethylase 4C in Pancreatic Ductal Adenocarcinoma
… is common in pancreatic ductal adenocarcinoma (PDAC). Lysine demethylase 4C (KDM4C) is one of the chromatin modifying proteins frequently overexpressed across multiple solid cancers and is linked to chromatin instability, increased cell proliferation, and enhanced stem cell-like behavior. We …
-
Dissecting the Role of Novel O-GlcNAcylation of NF-κB in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, with a mere 5-year survival of ~10%. This highlights the urgent need for innovative treatment options for PDAC patients. The nuclear factor κB (NF-κB) is a crucial transcription factor that is constitutively activated …
-
MicroRNAs in Pancreatic Ductal Adenocarcinoma: New Approaches For Better Diagnosis And Therapy
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies with less than an 8% 5-year survival rate, which has remained unchanged over the last 50 years. Early detection is particularly difficult due to the lack of disease-specific symptoms and reliable diagnostic …
-
Investigating the requirement of KRAS for the maintenance of pancreatic cancer
… which 85% is pancreatic ductal adenocarcinoma (PDAC), is the fourth leading cause of cancer death in the United States and a major cause of mortality and morbidity worldwide. Although recent advances in multi-agent chemotherapies have increased median survival in advanced disease, the 5-year …
-
Identifying genes that are required for the maintenance of pancreatic ductal adenocarcinoma
… maintenance of Pancreatic Ductal Adenocarcinoma (PDAC). PDAC is the 4th leading cause for cancer-related deaths and exhibits a 5-year survival rate of less than 5%. Since PDAC is a Kras-driven cancer in that greater than 90% of PDACs contain a Kras mutation, we tested genes that are downstream of …
-
Clinical Relevance of Immune Cells in Pancreatic Adenocarcinoma and their Implication in Immunotherapy
… microenvironment of pancreatic adenocarcinoma (PDAC). The aim was to delineate key features of immunologic and tumour components shaping the biology of pancreatic cancer. Immunotherapy has been largely explored as a promising anticancer approach but not convincingly introduced yet for this …
-
Characterizing PDK4 and PKC-Theta in Pancreatic Cancer and Cachexia
… patients with pancreatic ductal adenocarcinoma (PDAC) and is believed to cause 20% of cancer-associated deaths. Cachectic patients exhibit both metabolic abnormalities and systemic inflammation. Pyruvate Dehydrogenase Kinase 4 (PDK4) is upregulated in the skeletal muscles of many cancer cachexia …
Page 1 of 7